(A Novel Pharmacologic Regime for Elective Percutaneous Coronary Intervention) (REDUCED)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01031095
Recruitment Status : Completed
First Posted : December 14, 2009
Results First Posted : October 10, 2013
Last Update Posted : January 30, 2014
Information provided by (Responsible Party):
Hasan ARI, Bursa Postgraduate Hospital

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double (Participant, Investigator);   Primary Purpose: Treatment
Condition: Coronary Artery Disease
Intervention: Other: coronary intervention

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Low Dose Intracoronary Heparin Low dose intracoronary heparin treatment arm
Standard Therapy standard unfractionated heparin (UFH) treatment

Participant Flow:   Overall Study
    Low Dose Intracoronary Heparin   Standard Therapy
STARTED   100   100 
COMPLETED   100   100 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Low Dose Intracoronary Heparin Low dose intracoronary heparin treatment arm
Standard Therapy standard UFH treatment
Total Total of all reporting groups

Baseline Measures
   Low Dose Intracoronary Heparin   Standard Therapy   Total 
Overall Participants Analyzed 
[Units: Participants]
 100   100   200 
[Units: Participants]
<=18 years   0   0   0 
Between 18 and 65 years   80   80   160 
>=65 years   20   20   40 
[Units: Years]
Mean (Standard Deviation)
 59.11  (9.68)   58.99  (11.24)   59.06  (10.46) 
[Units: Participants]
Female   25   19   44 
Male   75   81   156 
Region of Enrollment 
[Units: Participants]
Turkey   100   100   200 

  Outcome Measures

1.  Primary:   Major Adverse Cardiac Events   [ Time Frame: 30 days ]

2.  Primary:   Major Adverse Cardiac Event   [ Time Frame: 30 days ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The intraprocedural use of a heparinised flush was not controlled; however, given the maximum amount that was allowed to be used, this is not likely to have significantly affected the activated clotting times. .

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Dr.Hasan ARI
Organization: Bursa Postgraduate Hospital
phone: 00902243605050 ext 1739

Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: Hasan ARI, Bursa Postgraduate Hospital Identifier: NCT01031095     History of Changes
Other Study ID Numbers: BYİEAH1
First Submitted: December 11, 2009
First Posted: December 14, 2009
Results First Submitted: January 21, 2012
Results First Posted: October 10, 2013
Last Update Posted: January 30, 2014